Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances by Li Liu & Xiao-Dong Liu
REVIEW ARTICLE
published: 10 December 2014
doi: 10.3389/fphar.2014.00273
Alterations in function and expression of ABC transporters
at blood-brain barrier under diabetes and the clinical
significances
Li Liu and Xiao-Dong Liu*
Center of Drug Metabolism and Pharmacokinetics, College of Pharmacy, China Pharmaceutical University, Nanjing, China
Edited by:
George Tegos, University of New
Mexico, USA
Reviewed by:
Adriana Maggi, University of
Milan, Italy
Filippo Caraci, University of
Catania, Italy
*Correspondence:
Xiao-Dong Liu, Center of Drug
Metabolism and Pharmacokinetics,
China Pharmaceutical University,
24 Tongjia Lane, Nanjing 210009,
Jiangsu, China
e-mail: xdliu@cpu.edu.cn
Diabetes is a systematic metabolic disease, which often develops a number of
well-recognized vascular complications including brain complications which may partly
result from the dysfunction of blood-brain barrier (BBB). BBB is generally considered
as a mechanism for protecting the brain from unwanted actions resulting from
substances in the blood and maintaining brain homeostasis via monitoring the entry
or efflux of compounds. ATP-binding cassette (ABC) family of transporters including
P-glycoprotein (P-GP) and breast cancer-related protein (BCRP), widely expressed in the
luminal membrane of the microvessel endothelium and in the apical membrane of the
choroids plexus epithelium, play important roles in the function of BBB. However, these
transporters are easily altered by some diseases. The present article was focused on the
alteration in expression and function of both P-GP and BCRP at BBB by diabetes and
the clinical significances.
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INTRODUCTION
The blood-brain barrier (BBB) is a multicellular vascular struc-
ture that separates the central nervous system (CNS) from the
peripheral blood circulation. The basic structural and functional
unit of the BBB is considered to be the so-called neurovascular
unit, which is composed of at least four cell types: brain capil-
lary endothelial cells comprise the brain capillaries of the cerebral
vasculature; pericytes sit on top of endothelial cells sharing the
same basal membrane; astrocytes surround the brain capillaries
and cover them with their endfeet; and neurons directly innervate
the microvasculature. Together these cells of the neurovascular
unit control barrier function. By tightly controlling the passage
of molecules and ions, instantaneously delivering nutrients and
oxygen according to current neuronal needs and protecting the
brain from toxins and pathogens, the BBB maintains an environ-
ment that allows neurons to function properly (Obermeier et al.,
2013).
Beyond barrier function, influx and efflux are actively regu-
lated at the blood-brain interface. At the molecular level, several
factors contribute to the unique functional role of the BBB.
Tight junctions in the capillary endothelium seal the spaces
between neighboring endothelial cells and represent a passive,
physical barrier that restricts paracellular diffusion of solutes
from blood to brain. To meet the high nutrient and energy
demand of the brain, influx transporters facilitate brain uptake
of glucose, amino acids, ions, and other nutrients from the
blood. ATP-binding cassette (ABC) efflux transporters on the
other hand extrude metabolic wastes into the blood and form
a selective, active barrier protecting the CNS by limiting xeno-
biotics, including toxins and a large number of drugs, from
entering the brain (Hartz and Bauer, 2011). Thus, the BBB
is a complex and fine-tuned transport machine that balances
influx of nutrients and efflux of wastes, toxins, and drugs to
maintain CNS homeostasis. The ABC efflux proteins of this
transport machinery are critical for the functional barrier and
present a formidable impediment to brain delivery of therapeutic
drugs.
ABC transporters belong to one of the largest andmost ancient
protein superfamilies and are highly conserved between species
and throughout evolution. ABC transporters are transmembrane
proteins that transport lipids, sterols, metabolic wastes, and ther-
apeutic drugs across intra- and extracellular membranes. These
transport processes are ATP-driven (active transport) and can,
therefore, be directed against a solute’s concentration gradient.
By now, the ABC transporter superfamily comprises 49 human
proteins divided into seven subfamilies that have been designated
ABCA to ABCG (Pahnke et al., 2014). They are expressed in every
cell type of the brain and mediate the transport of a wide variety
of substances.
For vertebrates, three ABC subfamilies, B, C, and G, con-
tain transporters that function as multispecific, ATP-driven
efflux pumps, and largely handle foreign chemicals (xenobi-
otics). As a rule, these ABC transporters are expressed in all
cells, but they are most highly expressed in barrier (such as
the BBB) and excretory tissues. Certainly, for an efflux trans-
porter to be effective in limiting blood to brain movement
of drugs and neurotoxicants and driving efflux of potentially
toxic metabolites, it should be localized to the luminal plasma
membrane. Functional studies with wild-type and knock-out
rodents as well as immunohistochemistry indicate that luminal
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membrane localization is certain for P-glycoprotein (ABCB1),
Multidrug Resistance-Associated Protein 2, MRP2 (ABCC2), and
breast cancer resistance protein (ABCG2) (BCRP). They have
the potential to affect many signaling molecules, waste products
of normal metabolism, therapeutic drugs, environmental toxi-
cants, and toxicant metabolites efflux out of the CNS (Miller,
2014).
Under the physiological state, BBB is generally considered as
a mechanism for protecting the brain from unwanted actions
resulting from substances in the blood and maintaining brain
homeostasis via monitoring the entry or efflux of compounds.
The BBB is not a static anatomical boundary, but a dynamic
interface capable of rapid response to stressors including hypoxia,
inflammation, trauma, and pain. In a number of brain patholo-
gies, loss of BBB function and changes in ABC transporter
expression have been suggested as a prognostic factor in the pro-
gression of these diseases (Wanek et al., 2013). Furthermore,
the BBB and ABC transporter dysfunction exacerbates numer-
ous diseases and pathologies including stroke, Alzheimer disease,
Parkinson disease, diabetes, acute liver failure, etc. Loss of BBB
integrity (i.e., leak or dysfunction of ABC transporters) exposes
the brain to potentially harmful concentrations of substances in
the peripheral circulation (e.g., ions, amino acids, neurotransmit-
ters, proteins, and other macromolecules) that may disrupt brain
homeostasis and adversely affect neuronal signaling (Abbott et al.,
2010).
Diabetes mellitus (DM) is a systematic metabolic disease,
which develops a number of well-recognized macro- and
microvascular complications related to endothelial dysfunction
(Stumvoll et al., 2005). Diabetic macrovascular complications
involve vessel obstructions, such as coronary artery diseases,
atherosclerosis, and peripheral vascular diseases. Microvascular
pathologies include retinopathy, nephropathy, and neuropathy.
Direct damage to small blood vessels, particularly by hyper-
glycemia, is manifested by endothelial dysfunction, dimin-
ished perfusion, abnormal endothelial cell proliferation, and
increased vessels permeability. Type 2 DM patients exhibit sim-
ilar microvascular damage within the CNS which may result in
increased incidence of cognitive deterioration, vascular demen-
tia, lacunar infarcts, hemorrhages and Alzheimer’s disease (AD)
(Serlin et al., 2011). These diabetes induced brain microvascu-
lar complications have disgusting consequences in dysfunction
of the BBB. Several phenomena known to disrupt the BBB
integrity, such as transient cerebral ischemia, hypertension and
hyperosmolality, are commonly associated with DM. DM is also
associated with changes in ABC transport functions in the cere-
bral microvessels. Under diabetic conditions, the integrity of
BBB is compromised and molecules that are normally confined
to the blood may enter the parenchyma leading to dramatic
changes in brain structure and function (Alves et al., 2012).
The diabetes-induced perturbations to cerebral microvessels may
disrupt homeostasis and contribute to long-term cognitive and
functional deficits of the CNS. The present article summarizes
and highlights the accumulating evidence in the literature which
describe the role of altered expression and function of both
P-GP and BCRP in the pathogenesis of diabetes and the clinical
significances.
ALTERATION IN BBB PERMEABILITY BY DIABETES
ALTERED BLOOD-BRAIN BARRIER STRUCTURE IN DIABETES MELLITUS
Alteration of cerebral microvessel structure, notably decreased
capillary density and disruption of tight junction function, is
one of the important reasons that diabetes disrupts BBB func-
tion. Although BBB permeability under diabetic status has been
widely investigated, the results are often controversial. Dai et al.
reported that no obvious differences in the staining pattern of
IgG and albumin were observed between brain samples of per-
sons with diabetes and controls (Dai et al., 2002). But Starr’s
study showed the increased BBB permeability to gadolinium
diethylenetriamine pentaacetic acid in patients with type 2 dia-
betes using gadolinium magnetic resonance imaging (Starr et al.,
2003). Antibodies against serum S100B and NSE (CNS proteins)
were found to be significantly increased in both type 1 and type 2
diabetic subjects compared to controls, implying that diabetes in
humans may be associated with alterations in the integrity of the
BBB (Hovsepyan et al., 2004). Animal experiment demonstrated
that diabetes significantly reduced cerebral tight junction pro-
tein occludin content, but another tight junction protein zonula
occludens-one content was not significantly altered, indicating
that diabetes alters the molecular anatomy of the tight junc-
tions in cerebral tissue by altering the content of select structural
proteins (Chehade et al., 2002).
METABOLIC CHANGES ON BBB IN DIABETES MELLITUS
Several studies have exhibited alterations in some nutrient trans-
porters at BBB under diabetic status. In hyperglycemic non-obese
diabetic mice, diabetes down-regulated both BBB permeability
to glucose and transporter maximal velocity of glucose without
alteration in the half-saturation constant (Cornford et al., 1995),
which may be attributed to the downregulated glucose trans-
porters (Hou et al., 2007). The decrease in expression of glucose
transporters at BBB impairs glucose transport into the brain,
leading tomental retardation (De Vivo et al., 1991) although there
was a report showing transport of glucose across BBB was not
altered in poorly controlled type 1 diabetes (Fanelli et al., 1998).
Influx of vitamin C to the brain is also mediated via the glucose
transporter, indicating that the decreased glucose transporter may
be responsible for depleted brain content of vitamin C in dia-
betic animals (Minamizono et al., 2006). In addition, diabetes
decreased monocarboxylic acid transporter expression, leading to
increase in BBB permeability to acetate acid (Mason et al., 2006).
Insulin uptake by brain was reported to increase under diabetic
status, however, this increase was not due to acute changes in
the serum levels of glucose or insulin, altered vascular space, or
catabolic events (Banks et al., 1997).
MECHANISMS OF BBB BREAKDOWN IN DIABETES MELLITUS
The underlying molecular changes leading to BBB dysfunction
under diabetic condition are not completely clear, butmay involve
increased expression of matrix metalloproteases (MMP), con-
fused ketone body levels and inflammation.
MMP activity is often increased in diabetic patients, indicat-
ing that higher plasma MMP activity increased BBB permeability
in diabetic condition via degradation of tight junction proteins.
Animal study (Hawkins et al., 2007a) showed that increase of BBB
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permeability to sucrose in streptozotocin-treated rats was associ-
ated with the decreased level of tight junction proteins occludin
and ZO-1 and the increase of MMP activity in plasma, which ver-
ified above deduction. Insulin treatment may attenuate the BBB
hyperpermeability to sucrose.
In diabetic ketoacidosis, the relationship between ketone bod-
ies and brain metabolism is well-documented (Roe et al., 1996).
Two ketone bodies β-hydroxybutyrate and acetoacetate cross BBB
via a monocarboxylic acid transport system. This transport was
increased by elevated blood concentration of ketone bodies. β-
hydroxybutyrate and acetoacetate increased BBB permeability
and induced brain edema via increasing the production of vas-
cular endothelial growth factor and vasoconstrictor endothelin-1
(Isales et al., 1999).
Inflammatory mechanisms underlying vascular pathology in
DM are possibly common to the vasculature in the periphery and
CNS. Formation of advanced glycation end products (AGEs) via
glycation of blood proteins is a consequence of hyperglycemia,
and it results in decreased kidney function and small vessels
pathology. AGEs accumulation may induce vascular inflamma-
tion by the interactions between AGEs and AGE-specific receptors
(RAGE) (Meerwaldt et al., 2009). AGEs activation of endothelial
RAGE promotes upregulation of endothelial adhesion molecules
including vascular cell adhesion molecule 1 (VCAM-1) and acti-
vates transcription factor nuclear factor-κB (NF-κB). The former
increases monocyte adhesiveness and vascular permeability while
the latter regulates multiple proinflammatory and proatheroscle-
rotic target genes in endothelial and vascular smooth muscle cells
as well as in macrophages (Piga et al., 2007).
ABC TRANSPORTERS AT BBB AND DIABETES
P-GP AND DIABETES
Diabetes is often associated with disorder of energy metabolism
and increases of pro-inflammatory cytokines in the systemic cir-
culation, which inferred that diabetes may alter expression and
function of ABC transporters at BBB, in turn, affect BBB per-
meability. We once reported that diabetes down-regulated P-GP
expression at BBB of diabetic rats, leading to increase in brain dis-
tribution of vincristine and rhodamine (Liu et al., 2006). Seventy
two hour exposure to serum of diabetic rats down-regulated func-
tion and protein levels of P-GP in primarily cultured rat brain
microvessel endothelial cells (rBMECs), which may be reversed
by adding of insulin (Liu et al., 2008a). We also found that the
effects of diabetes on Abcb1 mRNA levels was dependent on both
brain regions and Abcb1 species in streptozotocin (STZ)-induced
diabetic rats. Diabetes clearly down-regulated Abcb1a mRNA lev-
els in the cerebral cortex of diabetic rats, while up-regulated
Abcb1a mRNA levels in hippocampus. It was contrast to find-
ing in Abcb1a mRNA that the levels of Abcb1b mRNA cerebral
cortex of diabetic rats were increased rather than decreased. The
Abcb1b mRNA levels were not significantly affected by diabetes.
The increased P-GP proteins were also observed in hippocam-
pus of diabetic rats (Zhang et al., 2011). Similarly, expression of
P-GP in brain striatum of type 2 diabetic mice was increased (Wu
et al., 2009). In vivo study showed that insulin treatment not only
restored the impaired function and expression of P-GP at BBB by
diabetes, but also upregulated expression and function of P-GP at
BBB of normal rats (Liu et al., 2008a). In rBMECs, insulin dose-
dependently increased expression and function of P-GP, which
may be abolished by insulin receptor antibody (Liu et al., 2009).
Above results give a clue that low level of insulin in plasma
is a main factor resulting in impairment of P-GP expression
at BBB. Further investigation showed that insulin up-regulated
P-GP expression and function at BBB via activating PKC/NF-
κB pathway (Liu et al., 2009). NO is also considered to regulate
expression and function of P-GP, but our previous study on Caco-
2 cells showed that the effects of NO donors on P-GP function and
expression were dependent on exposure time. Four hour exposure
to NO donors impaired P-gp function and expression, whereas
24-h exposure stimulated P-gp function and expression (Duan
et al., 2012). Other factors such as inflammatory cytokines and
related molecules (von Wedel-Parlow et al., 2009; Poller et al.,
2010) may be involved in expression and function of P-GP at
BBB. Several studies have showed that cytokines exert dose-and
time-dependent modulation of efflux transporters. In RBE4 cells,
tumor necrosis factor-alpha (TNF-α) upregulated P-GP expres-
sion, accompanied by decrease in cellular uptake of the P-GP
substrate vinblastine (Yu et al., 2007). In isolated rat brain capil-
laries, TNF-α shows biphasic effects on the expression and activity
of P-GP with low dose decreasing but longer exposure (6 h)
increasing the expression and activity of P-GP. This is proba-
bly explained by differences in the signaling pathways activated
(Bauer et al., 2007). Following 72-h exposure to TNF-α, human
endothelial cells showed an increase of P-GP expression, but P-GP
activity was unaltered (Poller et al., 2010). In primary cultures
of porcine brain capillary endothelial cells, P-GP protein expres-
sion was transiently increased after TNF-α addition within 6 h
of incubation followed by a reduction after 24 and 48 h, whereas
the Abcb1 mRNA levels were not changed. It was also found that
Interleukin-1β (IL-1β) decreased the expression and activity of
P-GP (von Wedel-Parlow et al., 2009).
Absence of functional P-GP at BBB leads to highly increased
brain penetration of a number of important drugs, inducing
dramatically increased neurotoxicity, or fundamentally altered
pharmacological effects of the drugs on CNS. Phenobarbital, an
antiepileptic and sedative drug, was shown to be a substrate for
P-GP (Yang and Liu, 2008). The impaired function and expression
of P-GP on BBB of diabetic mice resulted in increased brain dis-
tribution and pharmacological effect of phenobarbital (Liu et al.,
2007a). Kamei et al. also reported that the systemic administra-
tion of second-generation H1-receptor antagonists (epinastine
and cetirizine) showed CNS depressant effects in STZ-induced
diabetic mice, accompanied by lower P-GP expression levels in
the whole brain (Kamei et al., 2005).
BCRP AND DIABETES
BCRP, another ABC transporter was reported to be downregu-
lated at BBB of diabetic rats, accompanied by increases in brain
distribution of prazosine and cimetidine (Liu et al., 2007b).
Insulin treatment may attenuate the impairment of Bcrp expres-
sion and function induced by diabetes. Neither aminoguanidine
(an inhibitor of advanced glycation end product) nor metformin
treatment prevented the impairment of Bcrp function and expres-
sion in brain cortex of diabetic rats although aminoguanidine
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and metformin levels of advanced glycation end product and
glucose in plasma diabetic rats were significantly suppressed
by aminoguanidine and metformin respectively, indicating con-
tribution of insulin to downregulation of BCRP. However, in
rBMECs, we found that unlike P-GP, insulin itself suppressed
rather than increased expression and function of Bcrp (Liu et al.,
2011), indicating existence of other factors impairing expres-
sion and function of BCRP at BBB. von Wedel-Parlow et al.
reported that TNF-α and IL-1β rapidly decreased Abcg2 mRNA
expression within 6 h. Long-term treatment with the vasocon-
strictor endothelin-1 (TNF-α downstream agent) induced Abcg2
protein expression. IL-1β caused a continuous decrease in pro-
tein expression of BCRP (von Wedel-Parlow et al., 2009). In
immortalized brain endothelial cells (hCMEC/D3), IL-1β, IL-6
and TNF-α significantly reduced levels of BCRP mRNA. IL-1β
showed the strongest inhibitory effect on expression of BCRP pro-
tein among the three proinflammatory cytokines. BCRP activity
was also significantly inhibited by IL-1β, IL-6 and TNF-α, assessed
by mitoxantrone uptake experiments (Poller et al., 2010).
ABC TRANSPORTERS, DIABETES AND ALZHEIMER’S DISEASE
ABC transporters mediate transport of Aβ across BBB
Recent studies have revealed that DM is a risk factor for cognitive
dysfunction or dementia, especially those related to AD. AD is
characterized by generation and deposition of amyloid β-peptide
(Aβ) within extracellular spaces of the brain, which is believed to
be the key player in the pathogenesis of AD (Vogelgesang et al.,
2002). Animal and clinical reports showed that diabetes increased
accumulation of Aβ in brain (Liu et al., 2008b; Alafuzoff et al.,
2009; Tomita et al., 2013) although roles of Aβ in AD progression
with diabetes need further verification. Possible relationships in
diabetes, BBB function, Aβ, and AD were shown in Figure 1.
Several studies (Kuhnke et al., 2007; Jedlitschky et al., 2010)
have showed that P-GP (ABCB1) mediated transport of Aβ across
BBB. Our previous study demonstrated that diabetes increased Aβ
level in hippocampus and cortex of rats. Insulin treatment may
restore the increase of Aβ level induced by diabetes. Further study
showed that the increase may partly come from both decrease in
efflux of Aβ from brain to blood and increase in influx of Aβ
from blood to brain, which were in line with impairment of P-GP
function and expression (Liu et al., 2008b). This finding infers
that increased accumulation of brain Aβ induced by diabetes at
least is attributed to impaired expression and function of P-GP at
BBB, which seems to explain that diabetic condition contributes
to the pathogenesis of AD (Liu et al., 2008b). In a clinical trial with
patients with mild to moderate AD using rifampicin, a potent
inducer of P-gp, a reduced cognitive decline was observed after
12 months of treatment, presumably because the drug was able to
improve the clearance of Aβ from the brain via the enhancement
of P-gp mediated transport (Loeb et al., 2004). It was interest-
ing that Aβ itself was reported to down-regulate expression of
P-GP in brain and dosing of the animals with the PXR ligand
pregnenolone-16 alpha-carbonitrile upregulated P-gp expression
and reduced cerebral β-amyloid deposition (Hartz et al., 2010),
inferring that accumulation of Aβ in turn further downregulated
P-GP expression at BBB.
BCRP also mediate transport of endogenous substances across
BBB. Several reports (Tai et al., 2009; Xiong et al., 2009; Do et al.,
2012) have verified that BCRP mediate transport of Aβ across
BBB. The role of ABCG2 in efflux of Aβ across BBB was inves-
tigated in Abcg2-null mice after intravenous injection of labeled
Aβ (Xiong et al., 2009; Shen et al., 2010; Zhang et al., 2013).
The results demonstrated that Abcg2-null mice significantly accu-
mulated more Aβ in their brains than wild-type mice. In situ
brain perfusion technique, GF120918 (dual inhibitor of Abcb1
and Abcg2) strongly enhanced the uptake of [3H] Aβ 1-40 by
the brains of Abcb1-deficient mice, but not by the brains of
Abcb1/Abcg2-deficient mice (Do et al., 2012). This role was fur-
ther confirmed by in vitro studies utilizing ABCG2 overexpressing
cells and hCMEC/D3 (Tai et al., 2009; Xiong et al., 2009). Above
results give a concept that BCRP and P-GP “team up and work
together” in transporting chemotherapeutics at BBB may pos-
sibly be extended to their handling of Aβ (Wolf et al., 2012).
Unlike P-GP, Xiong and colleagues reported that ABCG2 gene
was significantly up-regulated in the brains of AD patients and
AD animals (Xiong et al., 2009), however, this induction was
not copied by in vitro study on hCMEC/D3 (Xiong et al., 2009;
Kania et al., 2011). The up-regulation of ABCG2 in AD brain was
considered to be an adaptive response to relieve oxidative stress
and protect brain cells/tissue against ROS induced damage and
FIGURE 1 | Possible relationships in diabetes, blood brain barrier (BBB) function, β-amyloid and Alzheimer’s disease (AD).
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inflammatory response via inhibiting NF-κB signaling pathway
(Shen et al., 2010). ABCG2 was also reported to plays a pro-
tective role against oxidative stress and anti-inflammation (Shen
et al., 2010; Zeng et al., 2012). A study with HEK293 showed
that transfection with ABCG2 significantly inhibited ROS for-
mation by both tert-Butyl hydroperoxide and H2O2, indicating
that ABCG2 decreased oxidative capacity of HEK293 cells or/and
increased antioxidant capacity of the cells. Further investigation
showed that over-expression of ABCG2 decreased H2O2-induced
cell death, accompanied by decrease in IL-8 secretion and inhibi-
tion of NF-kB activation. In the brains of Abcg2-knockout mice,
the increased Aβ accumulation was in line with NF-κB activa-
tion. In Neural-derived mouse neuroblastoma cell line 2a-695
cells (expresses APP and produces β-amyloid peptides), trans-
fection with ABCG2 significantly decreased secretion of Aβ1-40
peptides and downregulated activities of α-, β, and γ- secretases in
cells (Shen et al., 2010). In Tg-SwDI/Abcg2-KO mice, Abcg2 defi-
ciency increases oxidative stress and alters inflammatory response
in the brain and exacerbates cognitive/memory deficit compared
with Tg-SwDI mice, wild type mice and Abcg2-KO mice, accom-
panied by decrease in levels of total brain GSH and increase in
levels of lipid/DNA oxidation (Zeng et al., 2012). All these results
show important roles of BCRP in accumulation of Aβ in brain of
diabetic patients and animals.
ABCB1 and ABCG2 are not the only ABC transporters found
to be associated with Aβ transport. Two further ABC transporters,
ABCA7 and ABCC1, appeared on the stage of AD. In AD patients
ABCA7 expression was found to be higher than in non-demented
people (Vasquez et al., 2013). Kim et al. evaluated the effect of
ABCA7 on Aβ pathology using ABCA7 knockout mice that were
crossed to the J20 AD model. They found a robust increase of
insoluble Aβ and plaque load in the brains of ABCA7-deficient
mice, but were unable to fully elucidate the mechanism behind
this observation. Using bone marrow derived macrophages they
showed a decreased ability of ABCA7 knockout cells to phago-
cytose oligomeric Aβ, pointing toward a possible mechanism of
action (Kim et al., 2013). ABCC1 was also found to influence
Aβ brain burden. An up to 14-fold increase of Aβ42 in ABCC1
knock-outmice is the so far greatest impact of an ABC transporter
in AD mouse models. Moreover, amyloid burden was reduced by
up to 80% in APPPS1 mice via functional activation of ABCC1
(Krohn et al., 2011). ABCC1 is expressed in capillary endothelia
of the blood–brain barrier, in neural stem and progenitor cells
(Schumacher et al., 2012). Its function is regulated by mitochon-
dria and influenced by mitochondrial polymorphisms (Scheffler
et al., 2012). However, it is also different to the other transporters
because one important site of high expression in the brain is the
choroid plexus.
Insulin/IGF-1 and TGF-β1 are involved in Aβ homeostasis
Insulin resistance, which is often associated with type 2 DM,
may induce a deficiency of insulin effects in the CNS. Some
research suggests that insulin resistance accelerates Alzheimer-
related pathology through its effects on Aβ metabolism. Recent
data also suggest that brains of patients with AD are insulin
and insulin-like growth factor-1 (IGF-1) resistant. β-amyloid
oligomers are responsible for downregulation of neuronal insulin
receptors, whereas Aβmonomers are able to activate insulin/IGF-
1 receptor signaling. It has been hypothesized that depletion of
β-amyloid monomers, occurring in the preclinical phase of AD,
might be the cause of early insulin/IGF-1 signaling disturbances
that anticipate cognitive decline (Giuffrida et al., 2012).
Insulin directly increases Aβ secretion from neurons by accel-
erating peptide trafficking to the plasma membrane (Gasparini
et al., 2001) and promotes Aβ degradation by regulating the
expression of the insulin-degrading enzyme, a metalloprotease
that catabolizes both insulin and Aβ (Zhao et al., 2004). IGF-
1 increases Aβ clearance from the brain by enhancing transport
of Aβ-carrier proteins (e.g., albumin and transthyretin) into the
brain (Carro et al., 2002). Hence, insulin and IGF-1 seem to
act in conjunction as regulators of brain Aβ content, and sys-
temic conditions altering their interplay could indirectly promote
Aβ oligomerization. For example, aging (the main risk factor
for AD) is associated with low serum levels of IGF-1 (Piriz
et al., 2011), and type 2 diabetes is associated with peripheral
hyperinsulinemia and low brain insulin levels that could result
in reduced Aβ clearance (Giuffrida et al., 2012). Insulin and
IGF-1 regulate multicargotransporters influencing trafficking of
several molecules including Aβ from the brain to the blood as
well as to the cerebrospinal fluid (CSF) and possibly vice versa.
Furthermore, insulin and related peptides regulate neurovascular
coupling changing regional blood flow. Thus, positive effects of
peripheral insulin/IGF-1 administration on AD pathology might
be due to changes in the BBB and/or in the transport between the
CSF/blood and the brain. Haploinsufficiency of the IGF-1 recep-
tor (IGF-1R) (IGF-1R+/- mice) as well as neuronal deficiency of
the insulin receptor (IR) (nIR-/- mice) or IGF-1R (nIGF-1R-/-
mice) leads to delayed Aβ accumulation when crossed withmouse
models for AD. Furthermore, insulin receptor substrate (IRS)-
2 knockout mice (IRS-2-/- mice) show reduced Aβ levels in
an Alzheimer background. These data suggest beneficial effects
of decreased neuronal insulin/IGF-1 signaling on Alzheimer-
pathology and question the therapeutic outcome of long-term
administration of insulin or IGF-1 in patients with AD (Zemva
and Schubert, 2014).
TGF-β1 is well-known to modulate blood vessel development
and maturation. Oligodendrocyte precursor cells (OPCs) are an
important source of TGF-β1 that supports BBB integrity dur-
ing development. OPCs derived TGF-β1 activates the MEK/ERK
pathway in cerebral endothelium via TGF-β receptor, and the
signaling cascade eventually increases the expression levels of
tight-junction proteins to promote the BBB integrity (Seo et al.,
2014). Reducing neuronal TGF-β1 signaling in mice resulted in
age-dependent neurodegeneration and promoted Aβ accumula-
tion and dendritic loss in a mouse model of AD (Wyss-Coray
et al., 2001). In cultured cells, reduced TGF-β signaling caused
neuronal degeneration and resulted in increased levels of secreted
Aβ and β-secretase-cleaved soluble amyloid precursor protein
(Tesseur et al., 2006). Hence, reduced neuronal TGF-β1 sig-
naling increases age dependent neurodegeneration and AD-like
symptoms. Improvement of TGF-β1 signaling may be a novel
therapeutic approach to AD, simultaneously targeting a neurode-
generative pathway and preventing Aβ deposition (Caraci et al.,
2012). A recent study reported that TGF-β1 potently regulates
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P-GP activity and ABCB1 mRNA at the developing BBB and
both ALK5 and ALK1 pathways are implicated in the regula-
tion of P-GP function (Baello et al., 2014). The research indicates
that aberrations in TGF-β1 levels at the BBB may lead to sub-
stantial changes in brain exposure to P-GP substrates including
Aβ, triggering consequences for neurodegenerative disease. It is
consistent with the above findings which illustrate that neuronal
TGF-β1 signaling has been impaired in AD, resulting in impaired
function and expression of P-GP at the BBB.
However, the regulation of BBB by TGF-β1 is contradictory
in DM. It is generally accepted advanced glycation endproducts
(AGEs) are considered to be an important factor in the forma-
tion of diabetic vascular complications. Takeshita et al. reported
that AGEs decreases in the expression of proteins comprising
tight junctions through the production of TGF-β1 in the BBB
(Takeshita et al., 2014). This finding suggests high level of AGEs
activate brain TGF-β1 signal pathway, leading to disturbance of
BBB under diabetic condition. Clinical and animal study also
showed that elevated plasma and urinary levels of TGF-β1 in dia-
betic patients and inhibition of TGF-β1 action is beneficial for
diabetic nephropathy (Li and Hölscher, 2007).
FUTURE PERSPECTIVES
ABC transporters including P-GP, BCRP and MRPs at BBB play
an important role in the transporting compounds across BBB.
The deliberate modulating ABC-transporters may mediate the
permeability of their substrates including drugs and endogenous
substances across BBB, affecting activity/toxicity of their sub-
strates on CNS. Based on current knowledge, we propose that
P-GP and BCRP are able to contribute to brain complications
under diabetic conditions. However, we remain far from the exact
contribution these transporters have to the disease. For exam-
ple, how diabetes affect ABC transporters in brain is still unclear.
Thus, a better understanding of ABC transporters functions in
the human brain is of major pharmacological importance to
the development and optimization of therapeutic strategies that
target these transporters.
Here, we only discussed alterations in expression and function
of P-GP and BCRP at BBB under diabetic status. In fact, other
transporters such as MRP2 (Hawkins et al., 2007b) and ABCA1
(Wang et al., 2012) were also investigated in brain of diabetic rats,
but the clinical significances needs further investigation. In addi-
tion, it should be mentioned that effects of diabetes on expression
and function of ABC transporters at BBB are often dependent on
species of ABC transporters, brain regions, duration of diabetes
and diabetic type, which may gave different results.
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